Biopôle Clermont-Limagne
Technology park for life sciences

The Biopôle Clermont-Limagne is a technopole (science technology park), fully dedicated to hosting and supporting businesses working in life sciences, spread over three sites located in Riom, Saint-Beauzire and Clermont-Ferrand.

Biopôle Clermont-Limagne offers biotech entrepreneurs a comprehensive range of services: not only equipped premises but also project support, communication, activities, access to partner networks, services to businesses and to their employees.  Over 50 businesses and organisations are currently growing their activities there.

DIRECTORY
of Biopôle
Clermont-Limagne
companies and
organisations

Do a search

Biopôle news

Hypercholesterolemia: Valbiotis announces the major success of the Phase II HEART clinical study.
14 June 2022

Hypercholesterolemia: Valbiotis announces the major success of the Phase II HEART clinical study.

ON-LIGHT will take part on the 2nd Regional Research Days in the Hospital Centre, organized by Emile Roux Hospital Center of Puy-en-Velay on 23 and 24 June 2022.
9 June 2022

ON-LIGHT will take part on the 2nd Regional Research Days in the Hospital Centre, organized by Emile Roux Hospital Center of Puy-en-Velay on 23 and 24 June 2022.

Clermont Innovation Week Roundtable: How can and should health and climate-conscious agricultural approaches create value in our territories?
5 April 2022

Clermont Innovation Week Roundtable: How can and should health and climate-conscious agricultural approaches create value in our territories?

Le SMO Biopôle Clermont-Limagne publie son Panorama & chiffres Clés 2021.
1 April 2022

Le SMO Biopôle Clermont-Limagne publie son Panorama & chiffres Clés 2021.

Valbiotis announces approval to launch the two Phase II/III INSIGHT and INSIGHT 2 clinical studies, the last step in the development of TOTUM•854 for the reduction of blood pressure.
14 February 2022

Valbiotis announces approval to launch the two Phase II/III INSIGHT and INSIGHT 2 clinical studies, the last step in the development of TOTUM•854 for the reduction of blood pressure.

The EIB, with the support of the European Commission, is financing a €30 million loan for Carbios’ enzymatic recycling technology to support the Circular Economy.
21 December 2021

The EIB, with the support of the European Commission, is financing a €30 million loan for Carbios’ enzymatic recycling technology to support the Circular Economy.

STRAINCHEM enters the semi-industrial phase with France Relance.
17 December 2021

STRAINCHEM enters the semi-industrial phase with France Relance.

Carbios receives support from the European Commission through the LIFE program.
29 November 2021

Carbios receives support from the European Commission through the LIFE program.

Valbiotis: preclinical results for TOTUM•070 in hypercholesterolemia, selected and presented at the American Heart Association (AHA) annual meeting.
19 November 2021

Valbiotis: preclinical results for TOTUM•070 in hypercholesterolemia, selected and presented at the American Heart Association (AHA) annual meeting.

See more news

Briefing

05 Aug 2022

OST Développement hosts 4 hives managed organically on its land in the heart of the Biopôle Clermont-Limagne.

See the briefing
28 Jul 2022

Valbiotis announces completion of recruitment for the Phase II/III REVERSE-IT clinical study with TOTUM•63 against prediabetes.

See the briefing
26 Jul 2022

METabolic EXplorer : appointment of Laurent Bastian as Chief Financial Officer

See the briefing
18 Jul 2022

The Jacquet plant is committed to reducing its water consumption by 15% with the signing of the PURE plan (IN FRENCH).

See the briefing
10 Jun 2022

METabolic EXplorer publishes its 2021 sustainability report (in french).

See the briefing
09 Jun 2022

Aptys Pharma is recruiting a analytical project manager and an analytical technician.

See the briefing
All the briefing